Neose Technologies Announces Formation of GlycoAdvance Advisory Board.

Business Editors

HORSHAM, Pa.--(BUSINESS WIRE)--March 19, 2001

Neose Technologies, Inc. (Nasdaq NM: NTEC) announced today that it has formed an advisory board to support its GlycoAdvance(TM) business.

The GlycoAdvance Advisory Board comprises six leading scientists with expertise in glycoproteins and glycosyltransferases.

David Zopf, M.D., Neose's Vice President for New Product Development, said, "We are excited that we have attracted this highly respected group of scientists to advise us in the development of our GlycoAdvance program. We have been very pleasantly surprised by the strong positive response in the biotechnology industry to our GlycoAdvance program. It is clear that problems with proper glycosylation of glycoproteins, including monoclonal antibodies, are pervasive in the industry, and Neose is developing the only systematic, flexible technology approach to these problems. The GlycoAdvance Advisory Board will help us set the future research and development direction for our effort."

The newly appointed members of the GlycoAdvance Advisory Board are:

Henrik Clausen, DDS. Dr. Clausen heads the Glycobiology Group in the Department of Oral Diagnostics, Copenhagen University. He has been a pioneer in the field of cloning the genes for glycosyltransferases that synthesize the human ABO blood group antigens and many other related enzymes important for the synthesis of carbohydrate chains of glycoproteins.

David James, Ph.D. Dr. James, from the University of Kent, UK, has made important discoveries relating minor structural changes in the carbohydrate chains of monoclonal antibodies to major changes in the ability of the antibodies to turn on immune effector functions.

Howard L. Levine, Ph.D. Dr. Levine is President of Bioprocess Technology Consultants, a company that provides technical and economic advice to enable glycoprotein manufacturing and downstream processing for many major biotechnology companies worldwide. Dr. Levine Previously had biological process development and manufacturing positions at Repligen, Amgen and Genentech.

James C. Paulson Ph.D. Dr. Paulson, Professor of Molecular Biology at Scripps Research Institute, is a world renowned glycobiologist and inventor on several key patents licensed to Neose that relate to core, enabling technologies for GlycoAdvance. Dr. Paulson was Vice President of Research and Chief Scientific Officer of Cytel Corporation prior to Neose's acquisition of Cytel's carbohydrate synthesis technology in 1999.

Harry Schachter, M.D., Ph.D. Dr. Schachter is Professor of Biochemistry at the University of Toronto and a recognized expert in the study of enzymes and mechanisms for glycoprotein glycosylation.

Pamela Stanley, Ph.D. Dr. Stanley is Professor of Cell Biology at Albert Einstein College of Medicine and a world leader in cytogenetics and glycosylation mechanisms in CHO cells, the cells most commonly used for production of therapeutic glycoproteins in the biotechnology industry.

Neose is a leading developer of proprietary technologies for the synthesis and manufacture of complex carbohydrates. The Company's proprietary enzymatic glycosylation technology platform enables the rapid and cost-effective synthesis of a wide range of complex carbohydrates in commercial quantities. Neose's GlycoAdvance(TM) technologies enable the completion and correction of glycosylation in recombinant glycoprotein discovery, development and manufacture. The Company uses its broad, enabling technology to produce complex carbohydrates for pharmaceutical, biotechnology, nutritional and consumer product applications.

For more information, please visit www.neose.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a more detailed discussion of these risks and uncertainties, any of which could cause the Company's actual results to differ from those contained in any forward-looking statement, see the "Risk Factors" section of Item 1 of the Company's Annual Report on Form 10-K for the year ended December 31, 1999.